Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis

The Lancet Psychiatry

Volumn 4, Issue 8, 2017, Pages 627-633

  Schoeler, Tabea ^a   Petros, Natalia ^a   Di Forti, Marta ^a   Klamerus, Ewa ^a   Foglia, Enrico ^a   Murray, Robin ^a   Bhattacharyya, Sagnik ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ILLICIT DRUG; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CANNABIS USE; CONTROLLED STUDY; DRUG USE; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RELAPSE; SELF REPORT; CANNABIS SMOKING; CLINICAL TRIAL; ENGLAND; EPIDEMIOLOGY; MULTICENTER STUDY; PSYCHOLOGY; RECURRENT DISEASE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LONDON; MALE; MARIJUANA SMOKING; MEDICATION ADHERENCE; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RECURRENCE; RISK FACTORS; YOUNG ADULT;

EID: 85022031155     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(17)30233-X     Document Type: Article

References (32)

1. Alvarez-Jimenez, M, Priede, A, Hetrick, S, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 139 (2012), 116–128.
2. Hong, J, Windmeijer, F, Novick, D, Haro, JM, Brown, J, The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry 33 (2009), 835–841.
3. Ascher-Svanum, H, Zhu, B, Faries, D, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry, 10, 2010, 2.
4. Almond, S, Knapp, M, Francois, C, Toumi, M, Brugha, T, Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 184 (2004), 346–351.
5. Birchwood, M, Todd, P, Jackson, C, Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 172 (1997), 53–59.
6. Olivares, JM, Sermon, J, Hemels, M, Schreiner, A, Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry, 12, 2013, 32.
7. Schoeler, T, Monk, A, Sami, MB, et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 3 (2016), 215–225.
8. Patel, R, Wilson, R, Jackson, R, et al. Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open, 6, 2016, e009888.
9. Schoeler, T, Petros, N, Di Forti, M, et al. Effects of continuation, frequency and type of cannabis use on relapse in the first two years following onset of psychosis—an observational study. Lancet Psychiatry 3 (2016), 947–953.
10. Verdoux, H, Lengronne, J, Liraud, F, et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatrica Scandinavica 102 (2000), 203–210.
11. Coldham, E, Addington, J, Addington, D, Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 106 (2002), 286–290.
12. Schoeler, T, Petros, N, Di Forti, M, et al. Examining the association between continued cannabis use and risk of relapse in first episode psychosis: a quasi-experimental investigation within an observational study. JAMA Psychiatry 73 (2016), 1173–1179.
13. Koskinen, J, Lohonen, J, Koponen, H, Isohanni, M, Miettunen, J, Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36 (2010), 1115–1130.
14. Colizzi, M, Carra, E, Fraietta, S, et al. Substance use, medication adherence and outcome one year following a first episode of psychosis. Schizophr Res 170 (2016), 311–317.
15. Foglia, E, Schoeler, T, Klamerus, E, Morgan, K, Bhattacharyya, S, Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis. Psychol Med, 2017, 1–15.
16. Navarro, S, Rodríguez, F, Acosta, FJ, García-Bello, M, Variables associated with nonadherence in clinically stable patients with bipolar disorder. Actas Esp Psiquiatr, 44, 2016, 157.
17. Baudin, G, Godin, O, Lajnef, M, et al. Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia. Schizophr Res 175 (2016), 161–167.
18. Compton, MT, Broussard, B, Ramsay, CE, Stewart, T, Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis. Schizophr Res 126 (2011), 71–76.
19. WHO. International statistical classification of diseases and related health problems, 2004, World Health Organization, Geneva.
20. Susser, E, Finnerty, M, Mojtabai, R, et al. Reliability of the life chart schedule for assessment of the long-term course of schizophrenia. Schizophr Res 42 (2000), 67–77.
21. Malla, A, Norman, R, Bechard-Evans, L, Schmitz, N, Manchanda, R, Cassidy, C, Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol Med 38 (2008), 1585–1593.
22. Wade, D, Harrigan, S, McGorry, PD, Burgess, PM, Whelan, G, Impact of severity of substance use disorder on symptomatic and functional outcome in young individuals with first-episode psychosis. J Clin Psychiatry 68 (2007), 767–774.
23. Hui, CL, Tang, JY, Leung, C-M, et al. A 3-year retrospective cohort study of predictors of relapse in first-episode psychosis in Hong Kong. Aust N Z J Psychiatry 47 (2013), 746–753.
24. Rosseel, Y, Lavaan: an R package for structural equation modeling. J Stat Softw 48 (2012), 1–36.
25. Lam, BY, Yang, Y, Raine, A, Lee, TM, Neural mediator of the schizotypy-antisocial behavior relationship. Trans Psychiatry, 5, 2015, e669.
26. Grech, A, Van Os, J, Jones, PB, Lewis, SW, Murray, RM, Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 20 (2005), 349–353.
27. González-Pinto, A, Alberich, S, Barbeito, S, et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 37 (2011), 631–639.
28. Barbeito, S, Vega, P, de Azúa, SR, et al. Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study. BMC Psychiatry, 13, 2013, 326.
29. González-Ortega, I, Alberich, S, Echeburúa, E, et al. Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis. PLoS One, 10, 2015, e0123707.
30. González-Pinto, A, González-Ortega, I, Alberich, S, et al. Opposite cannabis-cognition associations in psychotic patients depending on family history. PLoS One, 11, 2016, e0160949.
31. González-Ortega, I, Echeburúa, E, García-Alocén, A, Vega, P, González-Pinto, A, Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: study protocol for a randomized controlled trial. Trials, 17, 2016, 372.
32. Schoeler, T, Kambeitz, J, Behlke, I, Murray, R, Bhattacharyya, S, The effects of cannabis on memory function in users with and without a psychotic disorder: findings from a combined meta-analysis. Psychol Med 46 (2016), 177–188.